News
-
-
-
-
-
-
-
-
-
-
PRESS RELEASE
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a plant-based prescription drug, granted Orphan Drug Designation by FDA & EMA for treating rare pediatric diseases, including short bowel syndrome (SBS) & microvillus inclusion disease (MVID). Study presented at ELITE PED-GI Congress